Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials

Overview of attention for article published in BMC Cancer, February 2020

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 10 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 1,533 followers.

A recent publication on the risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma #cancer @biomed https://t.co/59IHBoCHnb

06 Mar 2020

Reply Repost Favourite

RT @ingentium_mel: Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced #melanoma #ca…

29 Feb 2020

Reply Repost Favourite

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced #melanoma #cancer: pooled analysis of #clinicaltrials. https://t.co/EUBYnmgENp

29 Feb 2020

Reply Repost Favourite

New article: Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials. https://t.co/b9DapQqwVY #melanoma #oncology

28 Feb 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.